


Smoking and Cardiovascular Risk

Athena Poppas, MD FACC
Associate Professor of Medicine
Brown University
Director, Echocardiography Laboratory
Rhode Island Hospital

Cardiovascular Risk Factors



- Age
- ☐ Family history
- ☐ Personal history of CVD
- ☐ Peripheral vascular disease
- Tobacco
- Hypertension
- Lipids
- Diabetes Mellitus



: MMWR, Vol.53(20); 427-431, May 28, 2004, CDC/NCHS.

Since 1965, smoking has declined 47% among adults, BUT

2003: 30% of high school boys, 25% girls report tobacco use

Tobacco in Women



- 20% of women in U.S. smoke
 - 37% NA, 22% W, 18%AA, 13% H, 7% A
- Cessation rates have declined more slowly in women c/w men
- 50% of heart attacks are caused by smoking
 - Leading preventable cause of CVD
 - Particularly in premenopausal women
- 1 to 4 cigarettes/day = 2.5 x risk

NEJM 1995; 332: 1758-1766 1998 Heart & Stroke Facts: American Heart Association



Cardiovascular risk and smoking

- Incidence of MI in one pack a day smokers: c/w nonsmokers
 - 6x increase in women
 - 3x increase in men
 - Circ 1996;93:450, BMJ 1998;316:1043
- Smoking greater risk of MI than diabetes
 - 15,152 cases/ 52 countries
 - Smokers OR 2.9, diabetes 2.4, HTN 1.9, lipids 3.2
 - Population attributable risk 35%, 10%, 18%, 49%
 - Lancet 2004;364:937.

Smokers present 1-2 decades 👯 earlier: Age of First MI

Women's Health Council of RI

Women:

Nonsmokers age 79

Smokers age 60

Men:

Smokers age 71

Nonsmokers age 64




FIGURE 2. Age at time of first acute myocardial infarction for male and female nonsmokers (NS) and smokers (S). Bars denote median values.



Smoking in patients with established CAD

- Increased mortality post-MI
 - 24% vs 15% *
 - 10% vs 4%
 - * no high school diploma
 - AJC 1993;71:1031
- Increased SCD in CAD patients:
 - 2.5x /8yrs
 - 8.1% vs 4.6% quitters vs 4.1% nonsmokers
 - Arch IM 2003;163:2301



Smoking and coronary revascularization

- Increased risk post CABG
 - 1000 patients/ 20 year follow up
 - Smoking cessation postop, indep predictor survival
 - Smokers: 1.7x increased risk death
 - Quitters survival benefit: 3% at 5 yrs and 14% at 15yrs
 - Quitters 1.4x reduced revascularization
 - JACC 2000;36:878
- Increased risk after percutaneous intervention
 - 1.8x increased mortality
 - 2x increased risk of MI
 - NEJM 1997;336:755.



Smoking affects all phases of atherogenesis

- Affects initiation and progression of atherosclerosis:
 - endothelial dysfunction
 - inflammation
 - oxidation of LDL
- Affects acute clinical events:
 - Plaque rupture and erosion
 - Thrombosis: increase platelets, decrease fibrinolysis
- Mechanism:
 - Increases oxidative stress, decreased NO availability

JACC 2004;43:1731

Pathophysiology of smoking and CV dysfunction Women's Health Council of RI Mainstream Smoke Sidestream Smoke >10¹⁷/g lasting hrs-mos >10¹⁵/puff lasting seconds Active Smoking Passive Smoking Tar-Phase Gas-Phase Components of Cigarette Smoke Deposited in Lung Free Radicals Directly Activation of Endogenous Activation of from Components of Neutrophil, Monocytes, Sources of Free Radicals ? Cigarette Smoke (Uncoupled NOS, Xanthine Platelets, T cells oxidase, METC, NADPH Oxidase) Oxidative Stress Cytokines (O2 -, H2O2, ONOO-) NO Generation or Bioavailabilty Inflammatory Gene Activation Vasomotor Prothrombotic Leukocyte Adhesion Smooth &↓ Fibrinolytic Dysfunction & Platelet Lipid & Inflamm. Muscle Factors Peroxidation Activation. Molecules Proliferation Genetic Predisposition & Other Cardiovascular Risk Factors including JACC 2004;43:1731 Initiation and Progression of Insulin Resistance Atherothrombotic Diseases

Smoking cessation for the primary care clinician

Strategy 1

Ask: systematically identify all tobacco users at every visit.

Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.

Strategy 2

Advise: strongly urge all smokers to quit.

In a clear, strong, and personalized manner, urge every smoker to quit.

Strategy 3

Identify smokers willing to make a quit attempt.

Ask every smoker if he or she is willing to make a quit attempt at this time.

Strategy 4

Assist: aid the patient in quitting

Help the patient with a quit plan.

Encourage nicotine replacement therapy or bupropion except in special circumstances.

Give key advice on successful quitting.

Provide supplementary materials.

Strategy 5

Arrange: schedule follow-up contact.

Schedule follow-up contact, either in person or via telephone.

Modified from Fiore, MC, Bailey WC, Cohen, JJ, et al. Smoking Cessation. Clinical Practice Guideline Number 18. AHCPR Publication No. 96-0692. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1996.



Safe in outpatient CAD patients, not tested in ACS

